JP2002518506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002518506A5 JP2002518506A5 JP2000555910A JP2000555910A JP2002518506A5 JP 2002518506 A5 JP2002518506 A5 JP 2002518506A5 JP 2000555910 A JP2000555910 A JP 2000555910A JP 2000555910 A JP2000555910 A JP 2000555910A JP 2002518506 A5 JP2002518506 A5 JP 2002518506A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen atom
- alkyl
- group selected
- heteroalkyl
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 67
- 125000004404 heteroalkyl group Chemical group 0.000 description 35
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 24
- 239000000203 mixture Substances 0.000 description 24
- -1 phosphoryl group Chemical group 0.000 description 14
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 3
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- 0 COc1cc(S(N(*)c(cc2*)cc(*)c2OP(O*)(O*)=O)(=O)=O)cc(OC)c1OC Chemical compound COc1cc(S(N(*)c(cc2*)cc(*)c2OP(O*)(O*)=O)(=O)=O)cc(OC)c1OC 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9068198P | 1998-06-25 | 1998-06-25 | |
| US60/090,681 | 1998-06-25 | ||
| PCT/US1999/013759 WO1999067258A1 (en) | 1998-06-25 | 1999-06-16 | Arylsulfonanilide phosphates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002518506A JP2002518506A (ja) | 2002-06-25 |
| JP2002518506A5 true JP2002518506A5 (enExample) | 2006-08-10 |
Family
ID=22223830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000555910A Ceased JP2002518506A (ja) | 1998-06-25 | 1999-06-16 | アリールスルホンアニリドホスフェート |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6211167B1 (enExample) |
| EP (1) | EP1090014B1 (enExample) |
| JP (1) | JP2002518506A (enExample) |
| AT (1) | ATE248845T1 (enExample) |
| AU (1) | AU763687B2 (enExample) |
| CA (1) | CA2335559A1 (enExample) |
| DE (1) | DE69911017T2 (enExample) |
| WO (1) | WO1999067258A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3421349B2 (ja) * | 1996-02-22 | 2003-06-30 | テュラリク インコーポレイテッド | ペンタフルオロベンゼンスルホンアミドおよび類縁体 |
| CO5170498A1 (es) * | 1999-05-28 | 2002-06-27 | Abbott Lab | Biaril sulfonamidas son utiles como inhibidores de proliferacion celular |
| US6355628B1 (en) * | 1999-07-29 | 2002-03-12 | Tularik Inc. | Combination therapy using pentafluorobenzenesulfonamides |
| CA2398219A1 (en) * | 2000-02-02 | 2001-08-09 | Warner-Lambert Company | Dual inhibitors of cholesterol ester and wax ester synthesis for sebaceous gland disorders |
| US6822001B2 (en) | 2000-11-03 | 2004-11-23 | Tularik Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| US20050250854A1 (en) * | 2000-11-03 | 2005-11-10 | Amgen Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| GB0224830D0 (en) * | 2002-10-24 | 2002-12-04 | Sterix Ltd | Compound |
| DE102007052174A1 (de) * | 2007-10-30 | 2009-05-07 | Ovd Kinegram Ag | Folienelement zur Sicherung eines Gegenstandes |
| WO2021099842A1 (en) * | 2019-11-22 | 2021-05-27 | 2692372 Ontario Inc. | Pentafluorobenzenesulfonamide derivatives and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1955207A (en) | 1931-09-16 | 1934-04-17 | Ig Farbenindustrie Ag | Mothproofing agent |
| DE622494C (de) | 1932-01-03 | 1935-11-29 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von Mono- bzw. Polynitropolysulfonen und deren Reduktionsprodukten |
| US2358365A (en) | 1940-08-03 | 1944-09-19 | Parke Davis & Co | Sulphonamide derivatives and process for obtaining the same |
| US2402623A (en) | 1943-06-24 | 1946-06-25 | Rohm & Haas | Nu-nitroaryl haloarylsulphonamides |
| CH361275A (de) | 1957-09-10 | 1962-04-15 | Geigy Ag J R | Verfahren zur Herstellung von neuen Arylsulfonarylamiden |
| GB938890A (en) | 1961-02-03 | 1963-10-09 | Boots Pure Drug Co Ltd | New fungicidal compositions and compounds |
| CH504416A (de) | 1966-12-05 | 1971-03-15 | Ciba Geigy Ag | Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen |
| GB1242057A (en) | 1968-07-04 | 1971-08-11 | Ici Ltd | Derivatives of 4-hydroxytetrafluoropyridine and the use thereof as plant growth regulators |
| NL174644C (nl) | 1970-04-13 | 1984-07-16 | Minnesota Mining & Mfg | Werkwijze ter bereiding van een herbicide verbinding; tevens werkwijze voor de bereiding van een preparaat met herbicide werking. |
| DE3623184A1 (de) | 1986-07-10 | 1988-01-14 | Kali Chemie Ag | Verfahren zur herstellung von n-fluorsulfonamiden |
| US4883914A (en) | 1987-08-17 | 1989-11-28 | American Cyanamid Company | Benzenesulfonyl carboxamide compounds useful as herbicidal agents |
| DE3804990A1 (de) | 1988-02-18 | 1989-08-31 | Basf Ag | Herbizid wirksame, heterocyclisch substituierte sulfonamide |
| JPH0651711B2 (ja) * | 1988-06-29 | 1994-07-06 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
| DE3905075A1 (de) | 1989-02-18 | 1990-08-30 | Hoechst Ag | Benzolsulfonamide und verfahren zu ihrer herstellung |
| FR2645537B1 (fr) | 1989-04-05 | 1994-03-04 | Fabre Medicament Pierre | Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique |
| FR2665440B1 (fr) | 1990-07-31 | 1994-02-04 | Lipha | Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant. |
| US5189211A (en) | 1990-08-01 | 1993-02-23 | Taisho Pharmaceutical Co., Ltd. | Sulfonamide derivatives |
| ATE167473T1 (de) | 1990-08-20 | 1998-07-15 | Eisai Co Ltd | Sulfonamid-derivate |
| US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
| US5529989A (en) * | 1995-01-09 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Pancratistatin prodrug |
| JP3421349B2 (ja) * | 1996-02-22 | 2003-06-30 | テュラリク インコーポレイテッド | ペンタフルオロベンゼンスルホンアミドおよび類縁体 |
| AU710173B2 (en) * | 1996-07-19 | 1999-09-16 | Tularik Inc. | Pentafluorobenzenesulfonamides and analogs |
| US6284923B1 (en) * | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
-
1999
- 1999-06-16 WO PCT/US1999/013759 patent/WO1999067258A1/en not_active Ceased
- 1999-06-16 AU AU45768/99A patent/AU763687B2/en not_active Ceased
- 1999-06-16 CA CA002335559A patent/CA2335559A1/en not_active Abandoned
- 1999-06-16 AT AT99928777T patent/ATE248845T1/de not_active IP Right Cessation
- 1999-06-16 DE DE69911017T patent/DE69911017T2/de not_active Expired - Fee Related
- 1999-06-16 JP JP2000555910A patent/JP2002518506A/ja not_active Ceased
- 1999-06-16 EP EP99928777A patent/EP1090014B1/en not_active Expired - Lifetime
-
2000
- 2000-06-14 US US09/595,398 patent/US6211167B1/en not_active Expired - Fee Related
-
2001
- 2001-02-07 US US09/779,419 patent/US6417176B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003514935A5 (enExample) | ||
| ES2521672T3 (es) | Formulaciones farmacéuticas para el tratamiento del cáncer | |
| CA2405796A1 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| JP2008514732A5 (enExample) | ||
| JP2001247459A5 (enExample) | ||
| CN101360495B (zh) | 对癌症病人给药mTOR抑制剂 | |
| JP2001514167A5 (enExample) | ||
| JP2005536553A5 (enExample) | ||
| HK1250645A1 (zh) | 取代的2，3-二氢咪唑并[1，2-c]喹唑啉类化合物的用途 | |
| JP2005538062A5 (enExample) | ||
| JP2015163628A (ja) | 腫瘍転移および癌の治療 | |
| JP2002518506A5 (enExample) | ||
| EP2054061A2 (en) | Combination therapy | |
| JP2002543144A5 (enExample) | ||
| CA2302568A1 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
| JP2024170590A (ja) | タウロリジン加水分解産物による神経芽細胞腫治療 | |
| JP2006516643A5 (enExample) | ||
| JP2003513075A5 (enExample) | ||
| JP2003522193A5 (enExample) | ||
| CN120713908A (zh) | 帕布昔利布在黏膜恶性黑色素瘤中的应用 | |
| JP2001519413A5 (enExample) | ||
| JPH1036365A5 (enExample) | ||
| RU96103685A (ru) | 1,2,5-тиадиазольные производные индолилалкил-пиридинил- и пиримидинил-пиперазинов, способ лечения или предотвращения развития сосудистой головной боли и фармацевтическая композиция | |
| RU2005105693A (ru) | Применение алкилфосфохолинов и лекарственное средство для лечения опухолевых заболеваний | |
| US20080207644A1 (en) | Therapeutic materials and methods |